India’s Pharma Sector Embraces Biosimilars and Biologics for High-Value Growth Transition.
The Indian pharmaceutical sector is poised for a transformative phase, focusing on high-value products such as specialty medicines, biologics, and novel therapies. This shift is backed by significant policy measures, including Production-Linked Incentives (PLI) schemes and the establishment of bulk drug parks. Currently, India is recognized as the “Pharmacy of the World,” exporting nearly 20% of global generic medicines and fulfilling about 60% of global vaccine demand, with exports projected to reach approximately $30.47 billion in FY25, reflecting a growth rate of 9.4%. The industry is moving away from traditional generics, aiming to enhance its competitiveness through complex generics and advanced manufacturing technologies.
This strategic pivot means that consumers can expect improved healthcare options as the pharmaceutical industry transitions to more sophisticated therapies that better address complex health needs. For the markets, this could signify an increase in foreign investment and greater collaboration with global entities, enhancing India’s position in the global supply chain. As the economy adapts, there might also be an uptick in job creation within the sector, fostering innovation and technological advancements that could further bolster economic growth. Enhanced product quality and diversified offerings are likely to improve patient outcomes and overall public health.
Looking ahead, the long-term outlook is contingent on sustained government support and robust investments in innovation and infrastructure. Continued emphasis on the PLI schemes and technological upgrades will be critical for manufacturers to maintain competitiveness and drive quality. Stakeholders are likely to advocate for further regulatory enhancements that would facilitate quicker approvals for high-value medicines. The government’s commitment to nurturing an environment conducive to research and development will play a crucial role in ensuring that the pharmaceutical sector not only meets domestic healthcare needs but also reinforces India’s standing as a global leader in pharmaceuticals.
Source: The Hindu
(Expert Note: This report was independently prepared by the Wealthova Economy team.)